Cytec Industries Inc. v Nalco Company

Link copied
Case Copied 71 min read

FEDERAL COURT OF AUSTRALIA

Cytec Industries Inc. v Nalco Company [2021] FCA 970

Appeal from: Cytec Industries Inc. v Nalco Company [2019] APO 2
File numbers: NSD 130 of 2019
Judgment of: BURLEY J
Date of judgment: 19 August 2021
Catchwords: PATENTS – appeal from decision of delegate of the Commissioner of Patents – patent application for method of reducing aluminosilicate scale – claims of patent application amended following delegate’s decision – hearing de novo
PATENTS – claim construction – whether claims include within their scope a reaction product mixture containing a single type of small molecule
PATENTS – validity – lack of support – comparison between invention specified in the claims and that described in the specification – technical contribution to the art – lack of support established
PATENTS – validity – lack of clear and complete description – classical sufficiency – whether specification enables skilled addressee to perform invention over the whole area claimed without undue burden – lack of clear and complete description established
PATENTS – validity – best method – characterisation of invention – where certain details in examples not disclosed – no failure to disclose best method
PATENTS – validity – lack of novelty – whether patent application anticipated by earlier filed specification – whether grace period provisions apply to “whole of contents” documents – grace period applies – lack of novelty not established
Legislation:

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth) ss 3 and Sch 6

Intellectual Property Laws Amendment (Raising the Bar) Bill 2011 (Cth)

Patents Act 1952 (Cth)

Patents Act 1990 (Cth) ss 18, 24, 40(2)(a), 40(2)(aa), 40(3), 59, 60, 65, 67, 79B, 105 and Sch 1

Convention on the Grant of European Patents, opened for signature 5 October 1973, 1065 UNTS 199 (entered into force 7 October 1977) art 83

Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1) (Cth) reg 4 and sch 6

Patents Act 1977 (UK) s 14(3)

Patents Regulations 1991 (Cth) regs 2.2(1A), 2.3(1A), 3.13D, 6.3 and 23.26(4)

Cases cited:

Commonwealth Scientific and Industrial Research Organisation v BASF Plant Science GmbH [2020] FCA 328; 151 IPR 181

CSR Building Products Ltd v United States Gypsum Company [2015] APO 72

Evolva SA [2017] APO 57

GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) Limited v Generic Partners Pty Limited [2018] FCAFC 71; 264 FCR 474

Jupiters Ltd v Neurizon Pty Ltd [2005] FCAFC 90; 222 ALR 155

Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd [2001] HCA 8; 207 CLR 1

Les Laboratoires Servier v Apotex Pty Ltd [2016] FCAFC 27; 247 FCR 61

Merck Sharp & Dohme Corporation v Wyeth LLC (No 3) [2020] FCA 1477; 155 IPR 1

Mont Adventure Equipment Pty Ltd v Phoenix Leisure Group Pty Ltd [2009] FCAFC 84; 176 FCR 575

Novartis AG v Johns & Johnson Medical Ltd [2010] EWCA Civ 1039; [2011] E.C.C. 10

Pfizer Overseas Pharmaceuticals & Ors v Eli Lilly & Co [2005] FCAFC…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Cytec Industries Inc. v Nalco Company and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] FCA 970
Decision Date

CaseChat Overview and Summary

The case of Cytec Industries Inc. v Nalco Company was heard in the Federal Court of Australia. The primary dispute concerned the validity of a patent application filed by Nalco Company for a method of reducing aluminosilicate scale in the Bayer process. Cytec Industries, the appellant, challenged the patent on several grounds, including lack of support, lack of a clear and complete description, lack of novelty, and failure to disclose the best method. The case was appealed from a decision of the delegate of the Commissioner of Patents, which was heard de novo by the court.

The court had to determine several legal issues, including whether the claims of the patent application included a reaction product mixture containing a single type of small molecule, whether the invention was sufficiently supported and described in the specification, and whether the patent application anticipated an earlier filed specification. The court also had to consider whether the patent application disclosed the best method of performing the invention and whether the invention was novel over the prior art.

In its reasoning, the court found that the claims of the patent application did not include a reaction product mixture containing a single type of small molecule. The court also found that the invention was not sufficiently supported and described in the specification, and that the specification did not enable a skilled addressee to perform the invention over the whole area claimed without undue burden. The court further found that the patent application did not anticipate an earlier filed specification, as the grace period provisions applied to the earlier specification. However, the court did not find that the patent application failed to disclose the best method of performing the invention.

The court's final orders were that the parties confer and supply to the chambers of Justice Burley, within 28 days, short minutes of orders giving effect to these reasons. If the parties were unable to agree to the terms of the short minutes, the areas of disagreement should be set out in mark-up. The proceedings were listed for case management at 9.30am on 13 October 2021.

Orders

Orders of the court

1. The parties confer and supply to the chambers of Justice Burley, within 28 days, short minutes of orders giving effect to these reasons.

2. Insofar as the parties are unable to agree to the terms of the short minutes referred to in order 1, including the appropriate order as to costs, the areas of disagreement should be set out in mark-up.

3. The proceedings be listed for case management at 9.30am on 13 October 2021.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Mr Bellwood affirmed one affidavit in these proceedings. In it he gives evidence about: the disclosure of the patent application; the disclosure of the WO 873 patent and how that compares to the patent application; and his response to the affidavits of Professor Easton. 2.3 Joint expert report and concurrent evidence Each of the witnesses joined in the preparation of a joint expert report. They also gave oral evidence in a concurrent session, during which they were cross-examined. I found that each expert gave frank and helpful evidence and was careful to refer to matters within their expertise. In this regard, Dr Power has expertise in process chemistry, particularly in the context of the Bayer process. Each of Dr Audet and Mr Bellwood also have experience in the Bayer process. Although Dr Audet has a good understanding of chemistry, he does not have experience working as a synthetic or organic chemist and frankly conceded that his understanding of some aspects under discussion were not as deep as that of Professor Easton, whose strength lies in his extensive experience in synthetic organic chemistry. Professor Easton, however, has only a general familiarity with the Bayer process, and so is less well-placed to give evidence about that process than the Bayer process experts (Dr Power, Dr Audet and Mr Bellwood), whose knowledge in that field was considerably more extensive. I have taken these matters into account in considering the evidence of each of the witnesses. 3. THE PRIMER The parties co-operated to produce a primer that sets out aspects of the common general knowledge as it stood at the priority date of the patent application. What follows is taken from that document. 3.1 The Bayer Process The Bayer process uses bauxite as the starting material. Bauxite is a rock containing many minerals, including aluminium hydroxides (gibbsite and boehmite) and aluminosilicate clays which are insoluble in water but soluble in strong caustic soda. The other main constituent of bauxite is ferrous (iron) oxide, which gives the bauxite its red appearance. The iron and most other minerals contained in the bauxite are not readily soluble in caustic soda. Silica and/or organic compounds are the main impurities present in bauxite. The amounts and levels of these impurities can depend on where the bauxite was mined. The organic impurities typically come from plant roots or soil that has decayed. The amount of organic impurity depends on how the soil is removed during the mining of bauxite, the geology of the area and climate. For example, bauxite from Western Australia has higher amounts of organic impurities compared to bauxite from the Northern Territory or North Queensland. To dissolve aluminium hydroxide in the form of gibbsite and/or boehmite, crushed and milled bauxite is added to a solution of caustic soda (sodium hydroxide), which has an alkaline pH at high temperature. This basic solution is known as the Bayer liquor, which continuously flows within a closed circuit comprising various machinery that facilitate different stages and conditions for the Bayer process. By taking bauxite, crushing it and heating it to over 100°C (and more typically at least 140-145°C where the bauxite is predominantly gibbsite or at least 250°C where the bauxite is predominantly boehmite) in caustic soda in a pressurised vessel, alumina is extracted into solution (referred to as liquor) and the rest of the minerals are left in a residual sludge/slurry (red mud). The mixture then flows through a series of decanters (operating at about 105°C under atmospheric pressure) in the presence of flocculants to settle and remove the red mud from the liquor, and the liquor is filtered (using, for example, a sand filter) to remove any residual mud particles, leaving a pregnant liquor.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.